<DOC>
	<DOC>NCT02367222</DOC>
	<brief_summary>The purpose of this database study is to assess if Arepanrix™ vaccination during the 2009 pandemic was associated with an increased risk of multiple sclerosis (MS) in Manitoba, Canada.</brief_summary>
	<brief_title>A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada</brief_title>
	<detailed_description>This observational, retrospective, propensity-score matched cohort study using the Manitoba Immunization Monitoring System (MIMS) and the hospital, physician, and prescription claims databases of the Manitoba Health (MH) Database System will assess if Arepanrix™ vaccination during the 2009 pandemic was associated with an increased risk of multiple sclerosis (MS) and other demyelinating conditions not ultimately leading to a multiple sclerosis diagnosis in Manitoba, Canada. The data will be collected form the following linked databases: - Manitoba Health (MH) administrative databases - Manitoba Immunization Monitoring System (MIMS) - Manitoba Health Population Registry (MHPR) - Drug Program Information Network (DPIN) - Hospital Abstract Database - The Medical Services database</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>The entire population of Manitoba is considered for inclusion. Individuals less than or equal to 6 months of age; Having less than one year of insurance coverage before the enrolment period; Not registered with MH during the enrolment period; Physician or hospitalization records indicating a diagnosis of any demyelinating condition between 1971 (earliest year for which information is available) and the index date.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>